Loading stock…

ICU Medical, Inc. (ICUI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ICU Medical, Inc.

ICUIMarket cap $3.99BPrice $159.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes IV therapy systems, infusion pumps, and consumables that hospitals rely on to safely deliver fluids and medication to patients. Its needle-free connectors help prevent millions of dangerous bloodstream infections every year in hospitals worldwide.

In Bastion Portfolios?

52W Return+35%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%3

Revenue Forecast

Rev CAGR (1y)-2%2

Rev CAGR (3y)+2%2

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+29603%10

EPS Growth Y+2+10%7

EPS Growth Y+3+7%6

Quality

Margins

EBIT Margin6%3

Net Income Margin1%2

Free Cash Flow Margin7%5

Debt

Net Debt/EBITDA2.93

Efficiency

ROE1%2

ROA1%2

Earnings Stability44

GEAR+VERY WEAK10

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)185

P/E Ratio (Forward 3y)155

P/BV1.97

EV Multiples

EV/EBITDA Fwd115

EV/EBIT Fwd146

Yield

Free Cash Flow Yield3.8%5

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return+3%7

YTD return+12%7

Mid term

Price vs 52wHigh83%6

1 year return+35%8

Long term

3 year return+37%5

5 year return-31%2

Risk Shield

Price Risk

Beta0.85

Volatility35%5

Free Cash Flow

Free Cash Flow Margin7%5

Free Cash Flow Yield3.8%5

Quality

ROCE4%3

Earnings Stability44

Net Debt/EBITDA2.93

02Growth

Is it actually growing, and how fast?

ICUIICU Medical

Revenue FY25$2.2B

GROWTH RATING↗

WEAK22 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+29603%10

EPS growth, FY27E+10%7

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue fell 0.7%/yr over the last 3 years and is set to grow around 2%/yr from here.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 78% of companies worldwide.

Revenue fell 0.7%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+3%7

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+35%8

3-year return+37%5

5-year return-31%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+3%) and so far this year (+12%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+37% over three years and -31% over five), behind 60% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ICU Medical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ICUIICU Medical

Revenue FY25$2.2B

GROWTH RATING↗

WEAK22 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%3

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+29603%10

EPS growth, FY27E+10%7

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue fell 0.7%/yr over the last 3 years and is set to grow around 2%/yr from here.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 78% of companies worldwide.

Revenue fell 0.7%/yr over the last 3 years, behind 70% of companies worldwide.3/10

Revenue is set to grow 2%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return+3%7

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return+35%8

3-year return+37%5

5-year return-31%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, but 17% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+3%) and so far this year (+12%).

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+37% over three years and -31% over five), behind 60% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on ICU Medical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community